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We evaluated the performance of the Bruker Biotyper and the bioMérieux Vitek MS with both the SARAMIS v4.09 and Knowl-
edge Base v2.0 databases for the identification of 203 non-glucose-fermenting Gram-negative rods that had previously been iden-
tified by 16S rRNA gene sequencing. Including those that underwent repeat testing, 96.6%, 90.1%, and 93.6% of isolates, respec-
tively, had identifications that agreed with the previous identification.
Matrix-assisted laser desorption ionization–time of flightmass spectrometry (MALDI-TOF MS) is quickly becoming
the primary means of identification of bacteria in the clinical mi-
crobiology laboratory. The performance of MALDI-TOF for
identification of routine organisms is well documented (reviewed
in reference 1), but few studies have been done on more atypical,
environmental organisms. Patients with cystic fibrosis (CF) be-
come chronically infected with a variety of environmental Gram-
negative organisms that are difficult to identify using phenotypic
methods, often requiring molecular methods, such as 16S rRNA
gene sequencing. In this study, we evaluated the performance of
three mass spectrometry platforms for use in place of 16S rRNA
identification of organisms isolated from our CF patients.
We utilized 203 archived isolates collected from CF patients
between 2009 and 2011 that could not be identified using tradi-
tional phenotypic methods. Isolates were initially identified by
16S RNA gene sequencing using MicroSeq reagents (Life Technol-
ogies, Carlsbad, CA) and the SmartGene IDNS database (Raleigh,
NC). Burkholderia cepacia complex members were further identi-
fied at the Burkholderia cepacia Research Laboratory and Reposi-
tory at the University of Michigan. Archived isolates were grown
on sheep blood agar at 35°C with 5% CO2 for 48 h before evalua-
tion on the MALDI-TOF platforms. The MALDI-TOF platforms
evaluated were the Bruker (Billerica, MA) Microflex with the Bio-
typer database (v3.2.1.1; 4,110 isolates), the bioMérieux (Durham,
NC) Vitek MS research-use-only (RUO) system with the SARAMIS
SuperSpectra (software v3.5) v4.09 database, and the bioMérieux Vi-
tek MS in vitro diagnostic (IVD) system with the v2.0 Knowledge Base
database. All isolates were spotted once initially, and if no satisfac-
tory identification was achieved, they were spotted again with and
without a 70% formic acid overlay. Isolates that were repeated
included those that did not generate an identification, those that
generated multiple identifications that contained both the target
identification and an unrelated organism, and those that were
undercalled (e.g., Burkholderia spp. as opposed to Burkholderia
gladioli or family Alcaligenaceae instead of Achromobacter spp.).
Satisfactory MALDI-TOF identifications were defined as those
that agreed with the sequence-based organism identification (Ta-
ble 1). We note that many of the organisms tested cannot be reli-
ably identified to species level based on the 16S rRNA sequencing
we perform and are therefore evaluated on the ability of the
MALDI-TOF instruments to provide an accurate identification to
the genus level only. Biotyper identification scores needed to be
2.0 for a species-level identification. SARAMIS scores of 75%
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TABLE 1 Organisms and identifications used in this study


























a These organisms were not able to be identified beyond being members of the
Burkholderia cepacia complex.
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and Knowledge Base scores of 80% (90% for Burkholderia) were
considered nonidentifications.
Upon initial testing, using the Vitek MS SARAMIS database,
171 of the 203 (84.2%) isolates matched the satisfactory identifi-
cation, 180 (88.7%) matched using the Vitek MS v2.0, and 181
(89.2%) matched using the Biotyper (Table 2). After initial test-
ing, 32 isolates were repeat tested using the Vitek MS SARAMIS,
yielding an additional 12 satisfactory identifications, for an overall
satisfactory identification rate of 90.2% including repeats. There
were 23 isolates that were repeat tested using the Vitek MS v2.0
platform, yielding 10 additional satisfactory identifications for an
overall satisfactory identification rate of 93.6%. The two isolates that
initially generated indeterminate identifications were satisfactorily
identified via repeat testing. Finally, 22 isolates were repeat tested
using the Biotyper; 15 additional correct identifications were
achieved, resulting in an overall satisfactory identification rate of
96.6%. For all three systems, the addition of formic acid to the
repeat spots did not significantly improve identification, contrary
to what is seen with yeast and some Gram-positive organisms (2,
3). Table 3 summarizes the performance of each database for the
most common organisms requiring 16S rRNA identification at
our institution.
One of the more difficult yet most important genera to identify
to species level from CF patient cultures is Burkholderia, especially
members of the Burkholderia cepacia complex. Historically, our
laboratory has used a combination of 16S rRNA gene sequencing
and referral testing to identify these organisms. We therefore eval-
uated the ability of the three MALDI-TOF databases to identify
Burkholderia spp., especially members of the Burkholderia cepacia
complex and related species (Table 3). All databases identified all
isolates to at least the genus level. The Vitek MS SARAMIS data-
base correctly identified all 41 isolates of B. gladioli, a species phe-
notypically similar to members of the B. cepacia complex (4), and
28 (75.7%) B. cepacia complex isolates to the species level. The
Vitek MS v2.0 identified 22 (59.5%) of the B. cepacia complex
isolates to the species level, while correctly identifying all 41 B.
gladioli isolates. Finally, the Biotyper identified 39 (95.1%) of the
B. gladioli isolates correctly to the species level and 26 (70.3%) of
the 37 B. cepacia complex isolates to species level. Burkholderia
multivorans and Burkholderia vietnamiensis were the members of
the complex best identified by all systems, while Burkholderia
cenocepacia was identified to the species level only by the Vitek MS
SARAMIS and the Biotyper. Burkholderia dolosa was not evalu-
ated in this study. Other members of the B. cepacia complex will
require better representation in the databases for consistent spe-
cies-level identification.
We also evaluated the ability of MALDI-TOF MS to identify
a subset of organisms (21 Burkholderia cepacia complex, 10
Chryseobacterium, 7 Achromobacter, 5 B. gladioli, and 4 Ralstonia
isolates) from selective media used in the isolation of Burkholderia
cepacia complex. We determined the performance of the Vitek MS
v2.0, for isolates grown on MacConkey agar (MAC), Burkholderia
cepacia agar (BC), Burkholderia cepacia selective agar (BCSA), and
oxidation/fermentation polymyxin-bacitracin-lactose (OFPBL)
medium for 48 h. We note that not all organisms grew on all media
tested, which is consistent with known growth characteristics. In-
TABLE 2 Performance of the MALDI-TOF systems
Result
Vitek MS SARAMIS (RUO) Vitek MS v2.0 (IVD) Bruker Biotyper













Correct 171 84.2 183 90.2 180 88.7 190 93.6 181 89.2 196 96.6
Undercalled 20 9.9 10 4.9 1 0.5 1 0.5 5 2.5 2 1.0
No ID 12 5.9 10 4.9 20 9.9 12 5.9 17 8.4 0 0.0
Indeterminatea 0 0.0 0 0.0 2 1.0 0 0.0 0 0.0 5 2.5
a Multiple identifications that contained both the target identification and an unrelated organism.




Vitek MS SARAMIS Vitek MS v2.0 BrukerBiotyper
Genus Family No ID Genus Family No ID Genus Family No ID
Achromobacter spp. 44 43 1 0 44 0 0 44 0 0
Chryseobacterium spp. 20 16 0 4 18 0 2 19 0 1
Ralstonia spp. 11 11 0 0 11 0 0 11 0 0
Species Complex Genus Species Complex Genus Species Complex Genus
Burkholderia cenocepacia 6 6 0 0 0 5 1 5 1 0
Burkholderia cepacia 3 2 0 1 2 1 0 1 2 0
Burkholderia contaminans 4 0 0 4 0 4 0 0 4 0
Burkholderia multivorans 16 16 0 0 16 0 0 16 0 0
Burkholderia vietnamensis 4 4 0 0 4 0 0 4 0 0
Burkholderia cepacia complex,
not further identifieda
4 0 0 4 0 4 0 0 4 0
Burkholderia gladioli 41 41 0 0 41 0 0 39 0 2
a These organisms were not able to be identified beyond being members of the Burkholderia cepacia complex.
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terestingly, very little difference was seen when the selective media
were used as opposed to blood agar. Thirty-one isolates grew on
the MAC plates; all 7 Achromobacter isolates maintained satisfac-
tory identifications, as did all 19 members of the Burkholderia
cepacia complex that grew and 4 of the 5 Burkholderia gladioli
isolates. From the BC plate, 38 isolates grew (8 Chryseobacterium,
4 Ralstonia, 5 B. gladioli, and 21 Burkholderia cepacia complex
isolates), and all had satisfactory identifications. For both BCSA
and OFPBL medium, 40 isolates (10 Chryseobacterium, 4 Ralsto-
nia, 5 B. gladioli, and 21 Burkholderia cepacia complex isolates)
grew, with all but one Chryseobacterium isolate being satisfactorily
identified by Vitek MS v2.0.
One of the benefits of identifying organisms by MALDI-TOF
MS is the potential cost savings that can be achieved. We therefore
calculated the cost to identify these 203 organisms on the various
platforms. For the calculations, we assumed that only 65% of any
one slide would be used at any one time and used our costs for
Vitek MS reagents and extrapolated costs for Bruker reagents
from the report of Tan et al. (5). We used the same labor costs for
both systems. We calculated a cost of $112.93 for sequencing and
a shipping cost of $24.72 for isolates referred for further identifi-
cation. Importantly, these calculations do not include the instru-
ment cost for either sequencing or MALDI-TOF. Therefore, based
on previous methods, the total cost for identification of the 203
isolates in this study was $23,839.43. The costs per isolate identi-
fied by MS, including repeats, were $0.82, $0.76, and $0.50 for the
Vitek MS SARAMIS, Vitek MS v2.0, and Biotyper, respectively.
The cost to use either of the MALDI-TOF platforms was signifi-
cantly less, saving over $20,000 to achieve all 203 identifications,
including repeat spotting and sequencing/referral identification
for those not adequately identified by MALDI-TOF.
The results of our study augment those presented previously
(6–8) by further challenging these MALDI-TOF systems with
large numbers of isolates not previously thoroughly evaluated,
including 78 Burkholderia, 44 Achromobacter, 20 Chryseobacte-
rium, and 11 Ralstonia isolates (Tables 1 and 3). All the isolates
tested in this study required molecular identification initially, due
to the inaccuracy of phenotypic identification. Additionally, our
study evaluated all three databases side by side and, importantly,
found that the three databases performed comparably, all identi-
fying 90% of the isolates correctly. Importantly, it has been pre-
viously shown that custom databases can achieve species-level
identification for 98% (9) of isolates such as members of the
Burkholderia cepacia complex, suggesting the impact of having an
extensive and appropriate database. It should be noted that the
Bruker Biotyper did identify the most organisms and had the
lowest associated total reagent cost for the 203 isolates in this
study. Based on our data, MALDI-TOF MS using either available
platform and any of the three databases is an accurate and cost-
efficient replacement for 16S rRNA gene sequencing for the iden-
tification of our difficult CF isolates. The biggest impact of imple-
menting MALDI-TOF MS, however, is the potential change in
workflow. A delay in identification with Burkholderia cepacia
complex members in particular may result in patients being
placed in isolation unnecessarily if the isolate does not belong to
this complex or, more concerning, not being placed in isolation
when they have an organism that is eventually identified as be-
longing to this complex. Additionally, CF patients may not be
eligible for lung transplantation when they are infected with this
organism complex (10, 11), further emphasizing the significant
impact on patient care that utilization of MALDI-TOF MS can
have in this setting: achieving reliable identifications for all of
these organisms the same day with minutes of hands-on time
compared to days for sequencing and weeks for referral identifi-
cation.
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